Real-world treatment patterns and outcomes with subsequent treatments following frontline brigatinib: a retrospective chart review
Year: 2026
Type: article
Abstract: This chart-review study retrospectively evaluated real-world treatment patterns and outcomes with subsequent treatments following frontline brigatinib in ALTA-1L. Patients previously enrolled in ALTA-1L were followed after brigatinib discontinuation. Among 40 patients who received subsequent systemic anticancer therapies, 30 (75%) received 2L ALK tyrosine kinase inhibitors (TKIs; lorlatinib, n = 16; alectinib, n = 8; crizotinib, n = 6), and 11 (28%) received 2L non–ALK TKI therapy, one of whom received it with alectinib. Real-world overall response rate on 2L treatment was 33% and 0% with ALK TKIs and non–ALK TKI therapy, respectively. Median (95% confidence interval [CI]) real-world time to treatment discontinuation was 34.7 months (4.6–not reached [NR]) for 2L ALK TKIs (lorlatinib, 37.2 months [6.0–NR]; alectinib, NR [1.1–NR]; crizotinib, 2.8 months [2.0–NR]) and 4.4 months (1.4–6.0) for 2L non–ALK TKI therapy. Median (95% CI) real-world progression-free survival was 16.1 months (4.4–NR) with 2L ALK TKIs (lorlatinib, 25.6 months [3.8–NR]; alectinib, 16.1 months [1.1–NR]; crizotinib, 2.4 months [2.0–NR]) and 6.1 months (1.7–NR) with 2L non–ALK TKI therapy. In conclusion, most patients advanced to a second ALK TKI following frontline brigatinib, with second- or third-generation ALK TKIs providing prolonged clinical benefit after brigatinib.
Source: Video Journal of Biomedicine
Authors: Myung-Ju Ahn, Angelo Delmonte, Sharmistha Ghosh, Maximilian Hochmair, Tsung-Ying Yang, James Chih-Hsin Yang, Ji-Youn Han, Karin Holmskov Hansen, Yanyu Wu, Yin Wan, Huamao Mark Lin, Julian Kretz, Bradley Hupf, Ahmet Melih Kurec, Eric N. Churchill, Robert J. Fram, Citadel Jungco Cabasag, Vishal Goriya, Yuzhe Zhao, Maria Rosario García Campelo
Institutions: Samsung Medical Center, Sungkyunkwan University, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Guy's and St Thomas' NHS Foundation Trust, Taichung Veterans General Hospital, National Taiwan University Hospital, Odense University Hospital, Takeda (United States), Takeda (Japan), IQVIA (United Kingdom)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7165137545